Medicenna Therapeutics Corp. (MDNA.TO)
CAD 1.13
(13.0%)
CAD 1.13
(13.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -19.66 Million CAD | 9.15% |
| 2022 | -21.64 Million CAD | 2.95% |
| 2021 | -22.3 Million CAD | -29.75% |
| 2020 | -17.18 Million CAD | -109.45% |
| 2019 | -8.2 Million CAD | -73.58% |
| 2018 | -4.72 Million CAD | 36.33% |
| 2017 | -7.42 Million CAD | 3.55% |
| 2016 | -7.69 Million CAD | -541.69% |
| 2015 | -1.19 Million CAD | -44.69% |
| 2014 | -829.1 Thousand CAD | -8.81% |
| 2013 | -762 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.04 Million CAD | -0.97% |
| 2023 FY | -18.67 Million CAD | 13.72% |
| 2023 Q3 | -4.77 Million CAD | 29.84% |
| 2023 Q1 | -4459.00 CAD | 99.74% |
| 2023 Q2 | -6.8 Million CAD | -152602.4% |
| 2023 Q4 | -4 Million CAD | 16.24% |
| 2022 Q2 | -7.1 Million CAD | -163964.67% |
| 2022 Q4 | -1.7 Million CAD | 79.62% |
| 2022 Q3 | -8.36 Million CAD | -17.68% |
| 2022 Q1 | -4330.00 CAD | -38.47% |
| 2022 FY | -21.64 Million CAD | 2.95% |
| 2021 Q4 | -3127.00 CAD | 36.14% |
| 2021 FY | -22.3 Million CAD | -29.75% |
| 2021 Q1 | -6.21 Million CAD | -8.86% |
| 2021 Q2 | -8233.00 CAD | 99.87% |
| 2021 Q3 | -4897.00 CAD | 40.52% |
| 2020 Q1 | -2.54 Million CAD | 4.49% |
| 2020 FY | -17.18 Million CAD | -109.45% |
| 2020 Q2 | -3.86 Million CAD | -51.93% |
| 2020 Q4 | -5.71 Million CAD | -8.29% |
| 2020 Q3 | -5.27 Million CAD | -36.36% |
| 2019 Q4 | -2.66 Million CAD | -10.97% |
| 2019 Q3 | -2.4 Million CAD | -27.13% |
| 2019 Q2 | -1.88 Million CAD | -46.42% |
| 2019 Q1 | -1.28 Million CAD | -19.95% |
| 2019 FY | -8.2 Million CAD | -73.58% |
| 2018 FY | -4.72 Million CAD | 36.33% |
| 2018 Q4 | -1.07 Million CAD | 37.22% |
| 2018 Q3 | -1.71 Million CAD | -92.66% |
| 2018 Q2 | -889.17 Thousand CAD | 15.28% |
| 2018 Q1 | -1.04 Million CAD | 19.54% |
| 2017 Q1 | -2.24 Million CAD | 48.69% |
| 2017 Q4 | -1.3 Million CAD | 40.04% |
| 2017 FY | -7.42 Million CAD | 3.55% |
| 2017 Q2 | -1.7 Million CAD | 24.13% |
| 2017 Q3 | -2.17 Million CAD | -27.85% |
| 2016 Q1 | -10.65 Thousand CAD | -20.73% |
| 2016 FY | -7.69 Million CAD | -541.69% |
| 2016 Q3 | -2.22 Million CAD | -36145.11% |
| 2016 Q4 | -4.37 Million CAD | -96.84% |
| 2016 Q2 | -6127.00 CAD | 42.51% |
| 2015 Q2 | -157.11 Thousand CAD | -964.29% |
| 2015 Q4 | -8827.00 CAD | 98.44% |
| 2015 Q3 | -565.78 Thousand CAD | -260.12% |
| 2015 FY | -1.19 Million CAD | -44.69% |
| 2015 Q1 | -14.76 Thousand CAD | 0.0% |
| 2014 FY | -829.1 Thousand CAD | -8.81% |
| 2013 FY | -762 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -144.255% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 46.708% |
| Helix BioPharma Corp. | -9.37 Million CAD | -109.828% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -618.563% |
| Satellos Bioscience Inc. | -15.46 Million CAD | -27.162% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | 41.81% |
| Sernova Corp. | -41.13 Million CAD | 52.194% |